A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium

C G Jackson,K N Moore,L Cantrell,B K Erickson,L R Duska,D L Richardson,L M Landrum,L L Holman,J L Walker,R S Mannel,K M Moxley,L Queimado,A Cohoon,K Ding,L E Dockery

JOURNAL OF CLINICAL ONCOLOGY（2022）

引用 4|浏览12

暂无评分

摘要

The combination of bevacizumab with rucaparib did not show significantly increased anti-tumor activity in all patients with recurrent cervical or endometrial cancer. However, patients with ARID1A mutations had a higher response rate and PFS6 suggesting this subgroup may benefit from the combination of bevacizumab and rucaparib. Further study is needed to confirm this observation. No new safety signals were seen.

查看译文

关键词

Rucaparib,Bevacizumab,Cervical cancer,Endometrial cancer,ARID1A

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要